GSK steps in to back Canadian vaccine project

GlaxoSmithKline ($GSK) is stepping in to support a Canadian project that tracks the use and effectiveness of flu vaccines at hospitals around the country. Faced with a cut in state funds, GSK--which provides Canada with a large annual stockpile of flu vaccines--says it will underwrite the Serious Outcomes Surveillance Network with a pledge of $12 million. And GSK isn't just replacing lost federal support; it's adding to their budget so investigators can add 40 hospitals to the group they monitor. "GlaxoSmithKline has nothing to do with the collection of the data, the analysis of the data or the reporting of the data," says a government health agency spokesperson. "They're just investing in allowing us to better answer the questions we were already asking." Story

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.